Scancell Appoints Head of Business Development

Scancell Holdings Plc

07 September 2023

 

7 September 2023

Scancell Holdings plc

("Scancell" or the "Company")

Scancell Appoints Dr Mandeep Sehmi as Head of Business Development

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, today announces the appointment of Dr Mandeep Sehmi as Head of Business Development, effective immediately.

Mandeep Sehmi brings more than 10 years of experience in business development and has previously held roles at leading UK biotech companies including at Abcam, where she managed and developed the cancer and metabolism portfolios, Cancer Research Technology, focussing on antibody out licensing, and Isogenica, where she was involved in deals for their antibody platform, including a multi-target deal with BioNTech. Mandeep joins Scancell from ImaginAb where she held the role of Director of Business Development and worked on a number of out-licensing opportunities for their lead asset with biotech and pharma in Immuno-oncology for cell therapies, vaccines and therapeutic antibodies. She holds a PhD in Cell and Molecular Biology and a Master's degree in Molecular Pathology and Toxicology from the University of Leicester, UK.

Prof Lindy Durrant, Chief Executive Officer of Scancell, commented: "The appointment of Mandeep is an exciting development for Scancell as we continue to expand our commercial capabilities. As communicated at the time of the recent business update, our strategic focus is on the continued development of the Company's two lead clinical assets SCIB1 and Modi-1. The value of our antibody platform, however, remains a powerful asset in enabling us to generate revenue through high value licence agreements and Mandeep, with her extensive network and business development experience in the antibody sector, will be invaluable as the Company continues to pursue attractive commercialisation avenues for our therapeutic assets. We welcome Mandeep to the team and look forward to working with her as we strive to bring innovative medicines to patients while maximising value for our shareholders."

Dr Mandeep Sehmi, Head of Business Development at Scancell, added: "Scancell's innovative cancer vaccines and antibodies have the potential to make a real difference in the treatment of cancer. The commercial licence agreement signed with Genmab, a leader in the field of antibody therapies for cancer, provides strong validation of the potential of our proprietary antibody platform and I am looking forward to joining the team to realise the commercial potential of these therapies for the benefit of patients."

-ENDS-

For further information, please contact:
Scancell Holdings plc	[phone]
Professor Lindy Durrant, CEO Dr Jean-Michel Cosséry, Non-Executive Chairman
Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker)	[phone]
Nicholas Moore/Samira Essebiyea/William Palmer-Brown (Healthcare Investment Banking)
Nick Adams/Nick Harland (Corporate Broking)
Panmure Gordon (UK) Limited (Joint Broker)	[phone]
Freddy Crossley/Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)

Consilium Strategic Communications	[phone]
Mary-Jane Elliott/Matthew Neal/Chris Welsh	[e-mail]

About Scancell

Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer and infectious disease. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope^® and ImmunoBody^® for vaccines and GlyMab^® and AvidiMab^® for antibodies.

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope^® and ImmunoBody^®) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab^®) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab^®).

For further information about Scancell, please visit: https://www.scancell.co.uk/

 

END